Send response to journal:
Re: WHY ONLY NEW DRUGS?
 

Email B.M HEGDE:
bmhegde@manipal.edu

Many other drugs which have been there longer in the market need also to be reviewed similarly; to give an example the anti-arrhythmic drugs. Some of these are potentially more dangerous than the arrhythmia for which they are prescribed! One could go on and on.

Some of the methods that the drug company studies use should be reviewed. One is that a new drug for any illness needs to be studied in a control study against another drug already in use which has proved its worth, to be called a better drug rather than against a placebo. The latest angiotensin receptor blockers could be cited in this context. They should be compared to ACE inhibitors and not placebo.

Last, but the most important, is to look into the financial background of the guidelines committee members, in the light of the new revelation (in print) of the guidelines on tissue plasminogen activators in stroke victims.

Money has brought in many of Man's ills, as shown by the study of the INNU community in Canada.

yours ever, bmhegde